Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019
March 20 2019 - 5:00AM
Heidelberg, Germany, March 20, 2019 – Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer, today announced that it will host a conference call on
Wednesday, March 27, 2019 at 8:30 a.m. ET to discuss its full year
2018 financial results and corporate developments.
The conference call will be available via phone
and webcast. To access the call, please dial +1 631 510 7495 for
U.S. callers, or +44 (0) 2071 928000 for international callers, and
reference conference ID 5559486 approximately 15 minutes prior to
the call. An audio webcast of the conference call can be accessed
in the “Webcasts” section on the “Investors” page of the Affimed
website at https://www.affimed.com/investors/webcasts/. A replay of
the webcast will be available on Affimed’s website shortly after
the conclusion of the call and will be archived for 30 days
following the call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage
biopharmaceutical company that engineers targeted immunotherapies,
seeking to improve patient outcomes through the power of innate
immunity. Affimed’s fit-for-purpose ROCK® platform allows innate
immune engagers to be designed for specific patient populations.
The Company is developing single and combination therapies to treat
cancers. For more information, please visit www.affimed.com.
Affimed Investor
Contact:Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed Media Contact:Anca
Alexandru, Head of Communications, EU IRE-Mail:
media@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024